

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

- (1) RESIGNATION OF EXECUTIVE DIRECTOR**
- (2) RE-DESIGNATION OF A NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR**
- (3) APPOINTMENT OF NON-EXECUTIVE DIRECTOR**
- (4) CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE AND**
- (5) CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE**

The Board hereby announces the following changes of the composition of the Board and its certain committees that with effect from December 30, 2021: (1) Ms. FU Yanjun resigned as the executive Director; (2) Mr. SHAN Baojie is re-designated from a non-executive Director to an executive Director; (3) Mr. HU Hui is appointed as a non-executive Director; (4) Mr. CHENG Libing resigned as a member of the Nomination Committee, Mr. LEE Kar Chung Felix resigned as the chairman of the Nomination Committee and remains as a member of the Nomination Committee, and Mr. SONG Qing is appointed as the chairman of the Nomination Committee; and (5) Mr. SHAN Baojie resigned as a member of the Audit Committee and Mr. HU Hui is appointed as a member of the Audit Committee.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Ms. FU Yanjun (“**Ms. FU**”) has resigned, with effect from December 30, 2021, as an executive Director due to other work arrangement within the Group. Ms. FU has confirmed that she has no disagreement with the Board and that

there is no matter in respect of her resignations which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Ms. FU for her valuable efforts and contributions to the Group during her tenure of office as an executive Director.

RE-DESIGNATION OF A NON-EXECUTIVE DIRECTOR TO EXECUTIVE DIRECTOR

The Board announces that Mr. SHAN Baojie (“**Mr. SHAN**”) has been re-designated from the role of non-executive Director to executive Director with effect from December 30, 2021.

Mr. SHAN, aged 50, obtained a master degree in Accounting from Renmin University (中國人民大學) in Beijing in June 2002 and a bachelor degree in Chemistry from Wuhan University (武漢大學) in Wuhan in July 1992. Mr. SHAN has been appointed as the non-executive director of the Company on August 25, 2021, and he is also currently the vice general manager of China Resources Healthcare Group Limited (“**CR Healthcare**”), the Company’s controlling shareholder, and is also taking the office as a director of a number of its subsidiaries. CR Healthcare, as one of the primary healthcare platforms of the China Resources Group, is specialised in the investment and operations management in the healthcare industry. CR Healthcare is committed to the long-term development of China’s medical and healthcare services, actively participates in China’s medical system reform, and proactively explores and involves in the investment, operation and management of hospitals and healthcare industries in the PRC. In addition to being the single largest shareholder of the Company, CR Healthcare also operates and manages a number of medical institutions in certain provinces of China including Liaoning, Jiangxi, Yunnan and Guangdong and Guangxi, etc. Prior to joining CR Healthcare, Mr. SHAN was with the Group from 2011 to 2016 as the executive general manager and then the vice general manager, and he was also an executive Director of the Company from February 2016 to November 2016. He had served in a variety of roles at the State Food and Drug Administration from 1998 to 2011. Mr. SHAN also completed a training program at the World Health Organization in 2007, where he gained experience in the U.S. pharmaceutical supervision and management system. From July 1992 to July 1998, Mr. Shan worked in the general manager’s office of the Northeast Pharmaceutical Group Co., Ltd. (東北製藥集團公司).

Mr. SHAN has entered into a service agreement with the Company for a term up to August 24, 2024, which can be terminated by either party by giving to the other party not less than one month’s notice in writing. Mr. SHAN will not be entitled to any remuneration from the Group in respect of his appointment as an executive Director.

Pursuant to the articles of association of the Company and the Corporate Governance Code as set out in Appendix 14 to the Rules Governing Listing of Securities on the Stock Exchange (the “**Listing Rules**”), Mr. SHAN will hold office as an executive Director until the next general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

Save as disclosed in this announcement, Mr. SHAN (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

As at the date of this announcement, Mr. SHAN does not have any interests in the shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there are no other matters relating to Mr. SHAN’s re-designation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board hereby extends its warmest welcome to Mr. SHAN for his new appointment.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. HU Hui (“**Mr. HU**”) has been appointed as a non-executive Director and a member of the Audit Committee with effect from December 30, 2021.

Mr. HU, aged 53, obtained a master’s degree in international economic law from the School of Management of Dalian Maritime University (大連海事大學) in June 1996; he graduated with a bachelor’s degree in the major of ocean-going vessel manoeuvring from the Maritime Department of Dalian Maritime University in July 1989. Mr. HU currently serves as the general manager of the Legal and Compliance Department (and Assets Management Department) of CR Healthcare (the controlling shareholder of the Company) and is also taking the office as a director of a number of its subsidiaries. He was previously the Senior Director of the Device Division of CR Healthcare (then named China Resources Medical Group Co., Ltd.) from November 2011 to November 2014, the General Manager of the Legal Department of CR Healthcare from November 2014 to November 2019, and the head of the Comprehensive Management Department of CR Healthcare from November 2019 to December 2020. Prior to this, Mr. HU served as a senior manager of China Resources Pharmaceutical Group Co., Ltd. from January 2008 to October 2011, and a senior manager of the Strategic & Management Department

of China Resources (Holdings) Co., Ltd. from June 2007 to December 2007. He worked at China Resources Investment Development Co., Ltd. from March 2001 to May 2007, and at China Resources Company Limited from July 1996 to February 2001.

Mr. HU has entered into a service agreement with the Company for a term from December 30, 2021 to December 29, 2024, which can be terminated by either party by giving to the other party not less than one month's notice in writing. Mr. HU will not be entitled to any remuneration from the Group in respect of his appointment as a non-executive Director.

Pursuant to the articles of association of the Company and the Corporate Governance Code as set out in Appendix 14 to the Listing Rules, Mr. HU will hold office as a non-executive Director until the next general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

Save as disclosed in this announcement, Mr. HU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

As at the date of this announcement, Mr. HU does not have any interests in the shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. HU that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board hereby extends its warmest welcome to Mr. HU for his new appointment.

CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE

The Board announces that Mr. CHENG Libing has resigned as a member of the nomination committee of the Company (“**Nomination Committee**”), Mr. LEE Kar Chung Felix has resigned as the chairman of the Nomination Committee and remains as a member of the Nomination Committee, and Mr. SONG Qing has been appointed as the chairman of the Nomination Committee with effect from December 30, 2021.

CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE

The Board announces that Mr. SHAN Baojie has resigned as a member of the audit committee of the Company (“**Audit Committee**”) and Mr. HU Hui has been appointed as a member of the Audit Committee with effect from December 30, 2021.

By Order of the Board of
China Resources Medical Holdings Company Limited
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, December 30, 2021

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. CHENG Libing, Ms. REN Yuan and Mr. SHAN Baojie as executive Directors; Mr. HU Hui as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Ms. CHIU Kam Hing Kathy and Mr. LEE Kar Chung Felix as independent non-executive Directors.